Abstract
Background: Rectal neuroendocrine tumors (NETs) are among the most common NETs. The aim was to validate European Neuroendocrine Tumor Society (ENETS)/North American Neuroendocrine Tumor Society (NANETS) staging and grading systems with regard to clinical outcomes. Methods: A comprehensive database was constructed from existing databases of the Mount Sinai Division of Gastrointestinal Pathology and the Carcinoid Cancer Foundation. Analysis was performed on 141 patients identified with rectal NETs seen at Mount Sinai Hospital between 1972 and 2011. Results: The median age was 52.7 years; 43% were males. Average tumor size was 0.88 cm. NETs <1 cm accounted for 75.6% of the tumors. Stage I, II, III and IV accounted for 79.4, 2.8, 5.0 and 12.8% of the tumors, respectively. G1 tumors accounted for 88.1%, G2 8.3% and G3 3.6%. Of G1 tumors, 94.6% were stage I and 5.4% were stage IV. The median survival time for all 141 patients was 6.8 years (range, 0.8-34.7 years). The overall 5-year survival rate was 84.4%. The 5-year survival rates for patients in stages I-IV were 92.7, 75.0, 42.9 and 33.2%, respectively. The 5-year survival rates for patients with G1-G3 tumors were 87.7, 47.6 and 33.3%, respectively. Univariate analysis of increased survival showed significance for lower stage, lower grade, smaller size, absence of symptoms and endoscopically treated tumors. Multivariate analysis showed that stage alone was statistically significant as the strongest predictor of survival. Conclusion: The results of our study validated ENETS/NANETS guidelines for staging and grading of rectal NETs in the US setting of a tertiary referral center. Staging according to ENETS/NANETS guidelines should be used in the treatment algorithm rather than size alone.
Journal Section:
Editor's choice
References
1.
Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM: The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011;40:1,18, vii.
[PubMed]
2.
Niederle MB, Hackl M, Kaserer K, Niederle B: Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society Classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer 2010;17:909-918.
[PubMed]
3.
Scherübl H: Rectal carcinoids are on the rise: early detection by screening endoscopy. Endoscopy 2009;41:162-165.
[PubMed]
4.
Shields CJ, Tiret E, Winter DC, International Rectal Carcinoid Study Group: Carcinoid tumors of the rectum: a multi-institutional international collaboration. Ann Surg 2010;252:750-755.
[PubMed]
5.
Yoon SN, Yu CS, Shin US, Kim CW, Lim SB, Kim JC: Clinicopathological characteristics of rectal carcinoids. Int J Colorectal Dis 2010;25:1087-1092.
[PubMed]
6.
Pinchot SN, Holen K, Sippel RS, Chen H: Carcinoid tumors. Oncologist 2008;13:1255-1269.
[PubMed]
7.
Chung TP, Hunt SR: Carcinoid and neuroendocrine tumors of the colon and rectum. Clin Colon Rectal Surg 2006;19:45-48.
[PubMed]
8.
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB: One hundred years after ‘carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the united states. J Clin Oncol 2008;26:3063-3072.
[PubMed]
9.
Modlin IM, Sandor A: An analysis of 8305 cases of carcinoid tumors. Cancer 1997;79:813-829.
[PubMed]
10.
Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934-959.
[PubMed]
11.
Godwin JD 2nd: Carcinoid tumors. An analysis of 2837 cases. Cancer 1975;36:560-569.
[PubMed]
12.
Landry CS, Brock G, Scoggins CR, McMasters KM, Martin RC 2nd: A proposed staging system for rectal carcinoid tumors based on an analysis of 4701 patients. Surgery 2008;144:460-466.
[PubMed]
13.
Shebani KO, Souba WW, Finkelstein DM, Stark PC, Elgadi KM, Tanabe KK, OTT MJ: Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 1999;229:815.
[PubMed]
14.
Konishi T, Watanabe T, Muto T, Kotake K, Nagawa H: Site distribution of gastrointestinal carcinoids differs between races. Gut 2006;55:1051-1052.
[PubMed]
15.
Sauven P, Ridge JA, Quan SH, Sigurdson ER: Anorectal carcinoid tumors. Is aggressive surgery warranted? Ann Surg 1990;211:67-71.
[PubMed]
16.
Rindi G, Kloppel G, Couvelard A, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B: TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007;451:757-762.
[PubMed]
17.
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A: AJCC (American Joint Committee on Cancer) Cancer Staging Manual, ed 7. New York, Springer, 2010, p 181.
[PubMed]
18.
Bosman FT, Carneiro F, Hruban RH, Theise ND (eds): WHO Classification of Tumours of the Digestive System, ed 4. Geneva, WHO, 2010.
19.
Sobin LH, Gospodarowicz MK, Wittekind C, International Union against Cancer: TNM Classification of Malignant Tumours, ed 7. Hoboken, Wiley-Blackwell, 2009.
20.
Konishi T, Watanabe T, Nagawa H, Oya M, Ueno M, Kuroyanagi H, Fujimoto Y, Yamaguchi T, Muto T: Treatment of colorectal carcinoids: a new paradigm. World J Gastrointest Surg 2010;2:153-156.
[PubMed]
21.
Anthony LB, Strosberg JR, Klimstra DS, Maples WJ, O'Dorisio TM, Warner RR, Wiseman GA, Benson AB 3rd, Pommier RF: The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (NETs) well-differentiated NETs of the distal colon and rectum. Pancreas 2010;39:767-774.
[PubMed]
22.
Caplin M, Sundin A, Nillson O, Baum RP, Klose KJ, Kelestimur F, Plockinger U, Papotti M, Salazar R, Pascher A: ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology 2012;95:88-97.
[PubMed]
23.
Jann H, Roll S, Couvelard A, Hentic O, Pavel M, Muller-Nordhorn J, Koch M, Rocken C, Rindi G, Ruszniewski P, Wiedenmann B, Pape UF: Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. BMC Cancer 2011;117:3332-3341.
[PubMed]
24.
Bernick PE, Klimstra DS, Shia J, Minsky B, Saltz L, Shi W, Thaler H, Guillem J, Paty P, Cohen AM, Wong WD: Neuroendocrine carcinomas of the colon and rectum. Dis Colon Rectum 2004;47:163-169.
[PubMed]
25.
Koura AN, Giacco GG, Curley SA, Skibber JM, Feig BW, Ellis LM: Carcinoid tumors of the rectum: effect of size, histopathology, and surgical treatment on metastasis free survival. Cancer 1997;79:1294-1298.
[PubMed]
26.
Zhong DD, Shao LM, Cai JT: Endoscopic mucosal resection (EMR) versus endoscopic submucosal dissection (ESD) for rectal carcinoid tumours: a systematic review and meta-analysis. Colorectal Dis 2013;15:283-291.
[PubMed]
27.
Jeon SM, Lee JH, Hong SP, Kim TI, Kim WH, Cheon JH: Feasibility of salvage endoscopic mucosal resection by using a cap for remnant rectal carcinoids after primary EMR. Gastrointest Endosc 2011;73:1009-1014.
[PubMed]
28.
Choi CW, Kang DH, Kim HW, Park SB, Jo WS, Song GA, Cho M: Comparison of endoscopic resection therapies for rectal carcinoid tumor: endoscopic submucosal dissection versus endoscopic mucosal resection using band ligation. J Clin Gastroenterol 2013;47:432-436.
[PubMed]
29.
Lee WH, Kim SW, Lim CH, Kim JS, Cho YK, Lee IS, et al: Efficacy of endoscopic mucosal resection using a dual-channel endoscope compared with endoscopic submucosal dissection in the treatment of rectal neuroendocrine tumors. Surg Endosc 2013, E-pub ahead of print.
[PubMed]
30.
Christensen M, Bulow S: Carcinoid tumors of the colon and rectum. Ugeskr Laeger 1998;160:4605-4609.
[PubMed]
31.
Kulke MH, Mayer RJ: Carcinoid tumors. N Engl J Med 1999;340:858-868.
[PubMed]
32.
Kim KM, Eo SJ, Shim SG, Choi JH, Min BH, Lee JH, et al: Treatment outcomes according to endoscopic treatment modalities for rectal carcinoid tumors. Clin Res Hepatol Gastroenterol 2013;37:275-282.
[PubMed]
33.
Son HJ, Sohn DK, Hong CW, Han KS, Kim BC, Park JW, et al: Factors associated with complete local excision of small rectal carcinoid tumor. Int J Colorectal Dis 2013;28:57-61.
[PubMed]
© 2013 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2013
You do not currently have access to this content.
